A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI (CELEBRATE)

• ClinicalTrials.gov Identifier: NCT04825743
• Recruitment Status: Recruiting
• First Posted: April 1, 2021
• Last Update Posted: February 10, 2023
• Sponsor: CeleCor Therapeutics
• Information provided by (Responsible Party): CeleCor Therapeutics

Study Description

Brief Summary:

This is a Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study. Subjects with STEMI will be enrolled in the ambulance if they meet all eligibility criteria. These subjects will be evaluated by (para)medics who transport the subjects to the participating hospitals in Europe and North America. Hospitals and ambulance services with experience in ambulance studies will be selected. Each subject will receive a single subcutaneous injection containing either zalunfiban Dose 1 (0.110 mg/kg) or zalunfiban Dose 2 (0.130 mg/kg) or placebo

Condition or disease	Intervention/treatment	Phase
ST-elevation Myocardial Infarction (STEMI)	Drug: zalunfiban; Drug: Placebo	Phase 3

Detailed Description:

Subjects will be screened in the ambulance based on the information available; those fulfilling the eligibility criteria who have provided verbal witnessed/short written/Exception from Informed Consent Requirements (EFIC) process informed consent will be randomized and enrolled in the study. Following a single weight-based dose of subcutaneous study drug administered by the ambulance staff, the patient will be transferred to the clinical site PCI center for angiography and intervention.

Regular standard of care is performed from the provision of informed consent through the last study mandated subject visit. Concomitant medications will be recorded. Treatment with IV P2Y12 antagonists or other αIIbβ3 receptor before PCI/angiography is prohibited. Demographics, concomitant medications, vital signs, and medical history will be collected in the CRF. Adverse events, bleeding events and injection site reactions will be collected. Angiography and PCI details will be recorded. Full written informed consent will be obtained. Additional blood samples for safety will be collected at 1, 6, 24 and 72 hours (or hospital discharge) post-PCI/angiography. Blood samples for high-sensitive cardiac troponin T (upon arrival and 24 hours post PCI/angiography) and NT-ProBNP (24 hours post PCI/angiography) will be assessed by central laboratory. Follow up phone contacts will occur at 30 days to report AEs, bleeding events, and injection site reactions, and 12-months to record mortality, and hospitalizations for heart failure or atrial fibrillation, and [in the event of stroke], 90 days (±2 weeks) to record the stroke disability.

Angiography/PCI data and ECGs will be evaluated at independent Core Laboratories. An independent, blinded Clinical Events Committee will provide central adjudication of all clinical endpoint events. A DSMB will examine the safety data in an ongoing manner and to alert the Steering Committee in case of clinically concerning safety issues that should lead to consideration of altering the trial, and can recommend modification of the study protocol based on pre-specified rules.

The duration of participation for each subject will be 12 months (± 1 month), including enrollment, study drug administration, hospitalization, and phone contact follow-up at 30 days (+ 7 days) and 12 months (± 1 month).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 2499 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 3 Prospective, Blinded, Randomized, Placebo Controlled, International Multicenter Study to Assess the Safety and Efficacy of a Single SQ Injection of Zalunfiban in Subjects With ST-elevation MI in the Pre-hospital Setting
• Actual Study Start Date: April 24, 2021
• Estimated Primary Completion Date: December 1, 2024
• Estimated Study Completion Date: December 31, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: zalunfiban Dose 1 (0.110 mg/kg); Subjects will receive a single subcutaneous injection containing zalunfiban Dose 1 (0.110 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival	Drug: zalunfiban; zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).; Other Name: RUC-4
Experimental: zalunfiban Dose 2 (0.130 mg/kg); Subjects will receive a single subcutaneous injection containing zalunfiban Dose 2 (0.130 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival	Drug: zalunfiban; zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).; Other Name: RUC-4
Placebo Comparator: Placebo; Subjects will receive a single subcutaneous injection containing Placebo in the ambulance after diagnosis of STEMI and before hospital arrival	Drug: Placebo; A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.

Outcome Measures

Primary Outcome Measures :

1. primary efficacy -clinical outcome [ Time Frame: at 30 days follow-up after a single subcutaneous injection of zalunfiban versus placebo ]

   As assessed by a 7-point scale. The 7 outcomes, ranking from worst to best are:

   1. Death (all cause) at 30 days follow-up
   2. Stroke at 30 days follow-up
   3. Recurrent MI (type 1 to 4 MI) at 30 days follow-up
   4. Acute stent thrombosis at 24 hours post-PCI/angiography
   5. New onset heart failure or rehospitalization for heart failure at 30 days follow-up
   6. MI with hs-cTnT levels ≥10x ULN at 24 hours post-PCI/angiography
   7. None of the above
2. primary safety- bleeding events [BARC criteria] [ Time Frame: after a single subcutaneous injection of zalunfiban versus placebo at 30 days post-PCI/angiography ]
   • To assess bleeding events (according to Global Use of Strategies to Open Occluded Coronary Arteries [GUSTO] severe or life threatening criterion for safety assessment and according to the Bleeding Academic Research Consortium [BARC] 3C and 5 criteria for information only)

Secondary Outcome Measures :

1. secondary efficacy-restoration of the coronary artery blood flow [ Time Frame: before PCI (or coronary angiography if no PCI is performed) ]
   To assess restoration of the culprit coronary artery blood flow (corrected Thrombolysis in Myocardial Infarction [TIMI] Frame Count) before intended PCI (or post coronary angiography in case no PCI is performed) after a single subcutaneous injection of zalunfiban versus placebo
2. efficacy-resolution of ST segment deviation [ Time Frame: 1 hour post-PCI/angiography ]
   To assess resolution of ST segment deviation post-PCI/angiography after a single subcutaneous injection of zalunfiban versus placebo
3. Efficacy-composite of all cause death, recurrent MI, acute stent thrombosis or blinded bail-out use of IV αIIbβ3 antagonists or IV P2Y12 antagonist [ Time Frame: at 30 days follow-up after a single subcutaneous injection of zalunfiban versus placebo ]
   To assess a composite of all cause death, recurrent MI, acute stent thrombosis or blinded bail-out use of IV αIIbβ3 antagonists or IV P2Y12 antagonist
4. Efficacy-acute stent thrombosis [ Time Frame: up to 24 hours post-PCI ]
   To assess incidence of definite, probable or possible acute stent thrombosis after a single subcutaneous injection of zalunfiban versus placebo
5. Safety throughout the study by AE reporting [ Time Frame: AEs up to 30 days follow-up; SAEs up to resolution/stabilization, the SAEs mortality, hospitalization for heart failure and atrial fibrillation up to 12-months follow-up ]
   Recording of AEs and SAEs fibrillation up to 12-months follow-up
6. Safety-platelet count [ Time Frame: before PCI/angiography, at the end of the PCI/angiography, 6 and 24 hours post-PCI/angiography and at hospital discharge/72-hours post-PCI/angiography (whichever occurs first) ]
   To assess platelet count after a single subcutaneous injection of zalunfiban versus placebo
7. Safety-bleeding events (ISTH and TIMI) [ Time Frame: at 30 days follow-up ]
   To assess bleeding events (according to International Society on Thrombosis and Haemostasis [ISTH] Major and TIMI Major for information only) after a single subcutaneous injection of zalunfiban versus placebo
8. Safety-bleeding events (GUSTO mild and moderate, BARC type 2, 3 and 5, ISTH minor and/or major and TIMI minor and major) [ Time Frame: 30 days follow-up ]
   To assess incidence of bleeding events according to GUSTO mild and moderate criteria, BARC type 2, 3 and 5 criteria, ISTH minor and or major bleeding, TIMI minor and major criteria
9. Safety-injection site reactions [ Time Frame: baseline, 1-hour post-PCI/angiography, hospital discharge/72-hours post-PCI/angiography, and at 30 days follow-up ]
   To assess the injection site reactions of a single subcutaneous injection of zalunfiban versus placebo

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Males aged ≥18 years or post-menopausal or surgically sterile females ≥50 years or ≥55 years (for Czech Republic study sites only).
2. Weight (by history) between 52 and 130 kg.
3. Subjects with STEMI, presenting with persistent ischemic chest pain (>10 minutes) and new ≥2 mm ST-segment elevation in two adjacent ECG leads, in whom the total duration of symptoms is 4 hours maximum. If time of symptom onset is uncertain, the cardiologist may be contacted to confirm inclusion criteria.
4. Exception from Informed Consent Requirements (EFIC) process, verbal witnessed/ short written informed consent, or written informed consent signed by subject or legally authorized representative/independent witness will be obtained in the acute phase by (para)medics, according to local applicable legal regulations. Subject is willing and able to give informed consent. Written informed consent will be obtained as soon as the subject's clinical condition allows it.

Exclusion Criteria:

1. Cardio Pulmonary Resuscitation (CPR) for current Out of Hospital Cardiac Arrest (OHCA).
2. Presenting with systolic blood pressure <90 mmHg (confirmed on repeat assessment) and heart rate >100 beats per minute (bpm).
3. Current known active coronavirus disease 2019 (COVID-19) infection (criteria according to local guidelines).
4. Currently treated with renal dialysis.
5. Current treatment with oral anticoagulation (Vitamin K antagonists [VKA] or direct oral anticoagulants [DOACs]).
6. Major surgery, or trauma or bleeding leading to hospitalization, within the past month.
7. Known history of ischemic or hemorrhagic stroke.
8. Known severe anemia (regular blood transfusion needed).
9. Previously enrolled in this study.
10. Participation in another clinical study with an investigational product or device within the past month.

11. Life expectancy less than one year.

    -

Contacts and Locations

Contacts

Contact: Robert S Hillman, PhD; 8587779750; rhillman@celecor.com

Locations

Canada

University of Alberta; Not yet recruiting

Edmonton, Canada

Principal Investigator: Rob Welsh, MD

Czechia

St. Anne's University hospital; Recruiting

Brno, Czechia

Principal Investigator: M Rezek, MD PhD

University Hospital Brno; Recruiting

Brno, Czechia

Principal Investigator: Prof. P. Kala, MD PhD

Hungary

Semmelweis University Heart and Vascular Center; Recruiting

Budapest, Hungary

Principal Investigator: B Merkely, MD, PhD

Bacs-Kiskun County Teaching Hospital; Recruiting

Kecskemét, Hungary

Principal Investigator: B Berta, MD, PhD

Netherlands

Zuyderland MC; Recruiting

Heerlen, Limberg, Netherlands

Principal Investigator: S Rasoul, MD PhD

Jeroen Bosch Ziekenhuis; Recruiting

's-Hertogenbosch, Netherlands

Principal Investigator: J Polad, MD PhD

Rijnstate Arnhem; Recruiting

Arnhem, Netherlands

Principal Investigator: R Pisters, MD PhD

Tergooi Blaricum; Recruiting

Blaricum, Netherlands

Principal Investigator: E K Arkenbout, MD PhD

Amphia Ziekenhuis; Recruiting

Breda, Netherlands

Principal Investigator: B.J.L. van den Branden, MD PhD

Ziekenhuis Gelderse Vallei; Active, not recruiting

Ede, Netherlands

Medisch Spectrum Twente; Recruiting

Enschede, Netherlands

Principal Investigator: K G Van Houwelingen, MD PhD

Leiden University Medical Center; Recruiting

Leiden, Netherlands

Principal Investigator: F Arslan, MD

Maastricht UMC; Recruiting

Maastricht, Netherlands

Principal Investigator: J Vainer, MD

St. Antonius Ziekenhuis; Recruiting

Nieuwegein, Netherlands, 3435 CM

Principal Investigator: J. M. Ten Berg, MD PhD

ETZ TweeSteden; Recruiting

Tilburg, Netherlands

Principal Investigator: B Zwart, MD PhD

UMC Utrecht; Recruiting

Utrecht, Netherlands

Principal Investigator: T P van de Hoef, MD PhD

Viecuri Medisch Centrum; Recruiting

Venlo, Netherlands

Principal Investigator: W S Remkes, MD

Isala; Recruiting

Zwolle, Netherlands

Principal Investigator: ATM Gosselink, MD PhD

Sponsors and Collaborators

CeleCor Therapeutics

Investigators

• Principal Investigator: Prof. Arnoud WJ Van 't Hof, MD PhD; Maastricht University Medical Center

More Information

• Responsible Party: CeleCor Therapeutics
• ClinicalTrials.gov Identifier: NCT04825743
• Other Study ID Numbers: CEL-03
• First Posted: April 1, 2021
• Last Update Posted: February 10, 2023
• Last Verified: April 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Myocardial Infarction; ST Elevation Myocardial Infarction; Infarction; Ischemia; Pathologic Processes; Necrosis; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases